Indeed, several treatments that target PD-L1/PD-1 interaction have been recently approved for cancer therapy, including monoclonal antibodies and immune checkpoint inhibitors, since tumors displaying a higher expression of PD-L1 appear to be more sensitive to such treatments [36]. This evidence concerns the gene PDCD1 and cancer.